• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.

作者信息

Chahine Zena, Meirson Tomer, Gilboa Shai, Mohyuddin Ghulam Rehman

机构信息

Division of Hematology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.

Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.

出版信息

Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf122.

DOI:10.1093/oncolo/oyaf122
PMID:40631771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12238937/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9077/12238937/53424580f644/oyaf122_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9077/12238937/53424580f644/oyaf122_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9077/12238937/53424580f644/oyaf122_fig1.jpg

相似文献

1
How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.作为一类推荐方案添加塞利尼索/硼替佐米/地塞米松如何可能会降低治疗效果。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf122.
2
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.基于塞利尼索的方案治疗复发/难治性多发性骨髓瘤的疗效和安全性：文献系统评价
Ann Hematol. 2022 Dec;101(12):2601-2610. doi: 10.1007/s00277-022-04999-1. Epub 2022 Oct 10.
3
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
4
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma.塞利尼索作为p53野生型、晚期或复发性子宫内膜癌患者维持治疗的评估。
Expert Rev Anticancer Ther. 2025 Jun 29:1-13. doi: 10.1080/14737140.2025.2522948.
5
Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.塞利尼索-硼替佐米-地塞米松：对既往治疗的多发性骨髓瘤的综述
Target Oncol. 2023 Mar;18(2):303-310. doi: 10.1007/s11523-022-00945-3. Epub 2023 Jan 9.
6
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.每周一次塞利尼索、硼替佐米和地塞米松与每周两次硼替佐米和地塞米松治疗多发性骨髓瘤患者（BOSTON）：一项随机、开放标签、3 期试验。
Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3.
7
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.isatuximab、硼替佐米、来那度胺与小剂量地塞米松用于不适宜移植的多发性骨髓瘤患者（REST）：一项多中心、单臂、2期试验
Lancet Haematol. 2025 Feb;12(2):e120-e127. doi: 10.1016/S2352-3026(24)00347-8.
8
Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition.自噬调节胶质母细胞瘤细胞对塞利尼索介导的XPO1抑制的敏感性。
Neuro Oncol. 2025 Jun 21;27(5):1210-1226. doi: 10.1093/neuonc/noae280.
9
A Spectrum of Understanding: A Qualitative Exploration of Autistic Adults' Understandings and Perceptions of Friendship(s).理解的光谱：对自闭症成年人对友谊的理解与认知的质性探索
Autism Adulthood. 2024 Dec 2;6(4):438-450. doi: 10.1089/aut.2023.0051. eCollection 2024 Dec.
10
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.复发和/或难治性多发性骨髓瘤治疗结局的系统文献回顾和网络荟萃分析。
J Clin Oncol. 2017 Apr 20;35(12):1312-1319. doi: 10.1200/JCO.2016.71.1663. Epub 2017 Feb 27.

本文引用的文献

1
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.塞利尼索、达雷妥尤单抗、硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者：II 期、非随机、多中心 GEM-SELIBORDARA 研究结果。
Haematologica. 2024 Jul 1;109(7):2219-2228. doi: 10.3324/haematol.2023.284089.
2
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.癌症药物试验中的偏倚评估——将无进展生存期用作主要终点如何会产生误导。
JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.
3
Diagnosis and Management of Multiple Myeloma: A Review.
多发性骨髓瘤的诊断与治疗：综述
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
4
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.每周一次塞来昔布、卡非佐米和地塞米松治疗卡非佐米难治性多发性骨髓瘤患者。
Br J Cancer. 2022 Mar;126(5):718-725. doi: 10.1038/s41416-021-01608-2. Epub 2021 Nov 20.
5
Informative censoring of surrogate end-point data in phase 3 oncology trials.信息性删失在 3 期肿瘤学试验中的替代终点数据。
Eur J Cancer. 2021 Aug;153:190-202. doi: 10.1016/j.ejca.2021.04.044. Epub 2021 Jun 26.
6
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review.美国多发性骨髓瘤随机试验中对照组的质量：系统评价。
Lancet Haematol. 2021 Apr;8(4):e299-e304. doi: 10.1016/S2352-3026(21)00024-7.
7
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.每周一次塞利尼索、硼替佐米和地塞米松与每周两次硼替佐米和地塞米松治疗多发性骨髓瘤患者（BOSTON）：一项随机、开放标签、3 期试验。
Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3.
8
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.口服塞利尼索联合地塞米松治疗三药难治性多发性骨髓瘤。
N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.
9
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.美国国家综合癌症网络（NCCN）指南推荐中超出食品和药物管理局批准的证据水平。
Ann Oncol. 2019 Oct 1;30(10):1647-1652. doi: 10.1093/annonc/mdz232.
10
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.